Detection of early-stage lung cancer: Computed tomographic scan or chest radiograph?  by Altorki, Nasser et al.
rates in the 70% range are often possible in patients
with stage I disease and may exceed 80% in those with
tumors measuring less than 3 cm.2 Thus, the argument
for early detection and its potential impact on survival
seems self-evident. Recent evidence suggests that spiral
computed tomography (CT) may increase the lung can-
cer detection rate by 4-fold to 10-fold compared with
chest radiographs and that nearly 80% of detected
lesions are stage I cancers.3,4
In the current study, we compared the stage distribu-
tion of a group of patients with non–small cell lung can-
cer (NSCLC) detected by CT scans with that of patients
whose tumors were detected on a routine chest radi-
ograph.
Methods
A retrospective chart review was performed to identify all
patients referred to the thoracic surgery service with biopsy-
proven NSCLC who were asymptomatic at presentation. Two
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lung cancer were diagnosed in 1999 and 158,000 deaths
resulted from the disease in the same year.1 Despite
advances in surgical, medical, and radiation therapy
over the past 3 decades, the overall 5-year survival
remains 10% to 12%. Most patients present with
advanced locoregional or disseminated disease for
which therapy is frequently ineffective. In contrast, cure
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groups of patients were identified: a group whose lesions
were detected by CT scan and another by chest radiography.
Patients were included in the chest radiography group (CxR
group) only if their chest radiograph was obtained as part of
a routine examination or before elective non-pulmonary
surgery. Patients were excluded if the chest radiograph was
prompted by any upper or lower respiratory tract symptoms
or if they had a prior malignant disease other than non-
melanoma skin cancer.
In the CT group, 16 patients were referred to one of us
(N.A.) through the Early Lung Cancer Action Project
(ELCAP), a bi-institutional prospective lung cancer screening
program established at Weill-Cornell Medical College and
New York University in 1993. These 16 patients represent part
of a group of 27 patients with screen-detected NSCLC previ-
ously reported by ELCAP.3 An additional 16 patients were
referred after CT scans done outside the ELCAP protocol. 
Follow-up was obtained by direct patient contact either by
telephone or in our lung cancer follow-up clinic. Follow-up
was also obtained from the referring physicians if direct
patient contact was not possible. Follow-up was complete
through April 2000 in 100% of patients in the CT group and
92% of patients in the CxR group.
Statistical analysis. Mean and SD or percentages were
used to describe each variable depending on whether the vari-
able was continuous or categorical. A 2-tailed t test was used
to compare continuous variables. The χ2 or Fisher exact test
was used to compare categorical variables. Survival for the
CxR group was analyzed by means of the Kaplan-Meier
product-limit method.
Results
Patient characteristics. Between January 1995 and
March 2000, 133 patients were evaluated and treated
for NSCLC detected by either a chest radiograph (n =
101) or CT scan (n = 32). The median age of the entire
group was 66.5 years. There were 70 male and 63
female patients. No differences in demographic fea-
tures were identified between the CT group and the
CxR group or between the ELCAP and the non-
ELCAP referred patients.
Surgical procedures. The distribution of surgical
procedures in both groups is shown in Table I.
Lobectomy was carried out in more than 90% of
patients in both groups. Mediastinoscopy was the only
procedure done in 1 patient in the CT group and in 2
patients in the CxR group. The in-hospital mortality for
the entire group of patients was 1.5% (2/132).
Pathology. Tumors with nonsquamous histologic
features were seen in 91% of the CT group (30/32) and
in 74% (75/101) of the CxR group (Table II). The dif-
ference approached but did not achieve statistical sig-
nificance (P = .059).
Maximal tumor size was determined by review of the
pathology report. The mean tumor size was 1.84 cm in
the CT group and 3.08 cm in the CxR group 
(P = .0001). Ten patients in the CT group had tumors
that measured 1 cm or less compared with 6 patients in
the CxR group. The CT group had a significantly high-
er proportion of T1 tumors than did the CxR group.
There was no significant difference between the 2
groups in the frequency of node-negative disease (77%
CT group, 68% CxR group; P = .3).
Stage distribution. The stage distribution for the 2
groups is shown in Table III. Eighty-one percent of the
patients in the CT group had stage I disease compared
with 70% of patients in the CxR group (P = .25).
However, a significantly greater number of patients had
stage IA disease in the CT scan group (62.5%) than in
the CxR group (39%) (P = .02). Overall, there was no
statistically significant reduction in the number of
patients with advanced stage disease (defined as stage
IIA or above) in the CT group compared with the CxR
group. However, there was a significant reduction in
advanced stage disease (P = .02) in the CT group with
the inclusion of stage IB cancers within “advanced
stage disease.”
Survival. Overall actuarial 5-year survival in the CxR
group was 42%. Five-year survival was 84% for stage IA,
55% for stage IB, and 28% for all other stages combined.
With a median follow-up of only 10 months, survival data
for the CT group are not yet ready for analysis. 
Discussion
Recent reports have suggested that CT may hold great
promise in the detection of early-stage lung cancer
compared with chest radiography.3,4 In the ELCAP trial,
1000 participants were recruited over a 5-year period
and screened by low-dose CT scans. Twenty-seven
NSCLCs were detected on the baseline screen, of which
only 7 were visible on a plain chest radiograph.
Significantly, more than 80% of patients had stage IA
disease.3 A study from Japan, where lung cancer screen-
ing has been used over the past decade, showed that the
lung cancer detection rate by CT scan was nearly 10-
fold higher than that achieved by chest x-ray films.4
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Table I. The distribution of surgical procedures
among the CT and CxR groups
CT CxR




In the present series, we have shown that patients in the
CT detection group had significantly smaller tumors (1.8
vs 3.0 cm) than those in the CxR group. Additionally,
63% of patients in the CT group had stage IA disease in
comparison with 39% in the CxR group. Since the 5-year
survival of stage IA NSCLC frequently exceeds 80%, the
detection of smaller and earlier stage tumors in the CT
group is a significant finding.
However, these data should be interpreted with cau-
tion because of a number of factors. The present series
is a retrospective study with its attendant limitations.
The possibility of a selection bias in either group can-
not be reasonably excluded. As previously stated, the
patients in the CT group do not represent an entirely
homogeneous group. Approximately 50% were
referred through a well-designed screening protocol
and the remainder represent random non-study cases.
Similarly, patients in the CxR group are a highly select-
ed group whose stage distribution may well have been
different had they been referred through a CxR screen-
ing program. Only a well-designed prospective screen-
ing protocol can reliably resolve these issues. 
Ideally, the detection of earlier stage disease will
translate into improved survival for patients with
NSCLC. However, the anticipated survival benefit may
reflect lead-time bias or over-diagnosis. Lead-time bias
can be addressed only after survival data in the CT
group have matured sufficiently to allow meaningful
conclusions. Over-diagnosis implies that early detec-
tion uncovers slow-growing, indolent tumors that may
never present a serious clinical menace. Conceptually,
the idea of NSCLC behaving in a “benign” way is
anathema to nearly all clinicians dealing with this dis-
ease. The issue of over-diagnosis has been elegantly
addressed by Flehinger, Kimmel, and Melamed,5 who
collected data on all patients with stage I disease
detected in 3 randomized trials for lung cancer screen-
ing sponsored by the National Cancer Institute.6-8
Although the majority of stage I tumors were surgical-
ly resected, a number of patients (n = 45) either
declined or were not offered resection because of med-
ical ineligibility. Five-year survival for surgically treat-
ed patients with stage I cancer was 70%, whereas it was
only 10% for the medically treated patients; nearly
80% of deaths in the latter group were related to lung
cancer. The authors noted that if “dormancy” was a bio-
logic feature of NSCLC, the surgically and nonsurgi-
cally treated patients would have had similar survivals. 
In the current series we have observed a significant
reduction in advanced stage disease (stage IB and
above) in the CT group compared with the CxR group.
These data suggest that CT screening may be of bene-
fit in improving the survival of patients with NSCLC.
Currently, no recommendations exist for screening
for lung cancer, either with sputum cytology or with
plain chest radiography. This policy is largely based on
3 clinical trials whose results were reported almost 2
decades ago. Two of these studies reported no addi-
tional benefit for sputum cytology as a screening
modality compared with chest radiography alone.7,8
The third study (The Mayo Lung Cancer Project)
resulted in a recommendation against radiographic
screening for lung cancer.6 However, flaws in the
design and execution of this study have called into
question the validity of its final conclusion. The find-
ings from the recently published ELCAP trial suggest
that low-dose CT scanning may be of substantial bene-
fit in screening high-risk groups for lung cancer. The
cost-effectiveness of large-scale screening for lung
cancer with CT scans is unknown at present. This
important issue should be addressed in a large, popula-
tion-based trial before a clear recommendation for CT
screening can be advocated. 
The overlap in patients and authors not withstanding, this
report represents work by its authors only. The methods and
conclusions presented here are not those of the ELCAP inves-
tigators as a whole.
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Table II. Tumor histology among the CT and CxR
patients
CT CxR
No. % No. %
Squamous 3 9 26 26
Adenocarcinoma 23 72 58 57
Bronchoalveolar 6 19 5 5
Large cell — — 6 6
Undifferentiated — — 6 6
Nonsquamous (overall) 29 91 75 74
Table III. Stage distribution among the CT and CxR
patients
CT CxR
No. % No. %
IA 20 62.5 39 38.6
IB 6 18.7 32 31.6
IIA 2 6.2 8 7.9
IIB 0 — 4 3.9
IIIA 3 9.3 16 15.8
IIIB 1 3 1 —
IV 0 — 1 —
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Discussion
Dr Joseph S. Friedberg (Philadelphia, Pa). Dr Altorki, the
conclusion of your abstract states that CT scans yield a high-
er incidence of stage IA and significantly fewer patients with
more advanced disease than that achievable by chest radiog-
raphy. This statement is supported by the ELCAP study and
other published reports but, from a scientific standpoint, I am
not sure your data support this conclusion. Your study was a
retrospective review of patients with biopsy-proven lung can-
cer initially detected by either CT or chest radiography. Your
statistics indicate that the mean size difference in the nodules
detected by the 2 modalities was significantly different.
However, the actual mean size is basically 2 cm for the CT
nodules and 3 cm for the chest radiography nodules. Thus,
my first question is this: Did any of the patients with nodules
detected by CT scan also have chest radiograms and, if so,
what percentage of those patients had nodules visible on CT
but not on chest radiography? Only a demonstration that the
stage IA tumors were visible on CT but not on plain chest
films would support your conclusion that the CT scans were
responsible for this finding. 
In support of your argument, however, are observations we
have made at the University of Pennsylvania with respect to
incidental nodules found in patients evaluated for lung vol-
ume reduction surgery. Since 1995, approximately 250
patients have been set up for this procedure. This group of
patients had an average smoking history of 30 to 60 pack-
years and were otherwise similar to your group of patients
with lung cancer. All of these patients had both chest radi-
ographs and CT scans. Twenty-six of the 250 were found to
have suspicious nodules by radiographic criteria and, to date,
23 have undergone excisional biopsies. Unlike other reports,
only 4 of the 23 nodules were cancer and the remainder were
predominantly Mycobacterium avium intracellulare infec-
tions or scars. Two thirds of the 26 nodules were visible only
on CT scan and not on plain chest radiographs, including 3 of
the 4 primary lung cancers. To a great extent, this was a func-
tion of the small size of the nodules, many less than 1 cm.
Thus, in effect, approximately 10% of this high-risk group
had suspicious radiographic findings on CT scan, of which
only a third were visible on plain films. Approximately 2%
had lung cancers, of which only one quarter were identified
on plain chest x-ray films. In this setting, all radiographs were
nonspecific, but the CT scans certainly proved more sensitive
than plain chest x-ray films as a screening test. 
In this day and age, a major issue is cost. Given that you
only reviewed patients who were sent for surgical resection,
we have no idea how many patients were screened and what
the incidence was of benign nodules detected by the screen-
ing. Could you tell us approximately how many patients were
screened or subjected to biopsy for benign disease for every
cancer detected? Roughly, what sort of cost per tumor detect-
ed would you estimate for each modality? 
To prevent prohibitive expense, what criteria do you rec-
ommend as an indication for CT screening, and can you fore-
see any supplemental assays to increase the specificity of
radiographic screening? 
The National Cancer Institute issued a press release on
April 11, 2000, which is aimed at addressing questions
regarding the current status of CT screening for lung cancer.
It states: “Promising evidence from several studies shows that
the scans can detect small lung cancers, but detecting these
early tumors has not been proven to reduce the likelihood of
dying from lung cancer, the gold standard for any cancer
screening test.” On the other hand, I would concur with the
statement from your manuscript that “the argument for early
detection and its potential impact on survival seems self-
evident.” That said, however, you do report 3 of 32 cancer-
related deaths for your patients with CT-detected lung can-
cers at a median follow-up of 10 months. Although this sta-
tistic in and of itself is not significant, I think it does support
the National Cancer Institute’s call to establish increased sur-
vival as the bottom line. 
Dr Altorki. Dr Friedberg, thank you for your comments.
You posed several questions and I will try to answer them all. 
You first asked whether these lesions were also visible on
a chest x-ray film. I can answer that question in 2 ways. One
is to say that our ELCAP series, which is not the subject of
the present report, showed that lung cancer was visible on
chest films in only 7 of the 27 patients with lung cancer. In
the current series, some of the patients in the CT group did
not have chest x-ray films, so it is hard for me to answer your
question specifically. 
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You inquired about the overall denominator of the patients
screened and how many had benign lesions. Again, I stress,
this is not a screening study. The screening study by ELCAP
comprised 1000 patients. Two hundred fifty were found to
have nodules, and 27 of them had cancer. The great majority
of the nodules that you see on a CT scan are going to be
benign nodules, and the number of cancers you find will vary
depending on the entry criteria and how strict you are with
respect to the population being screened. If you look at the
population screened in Japan, where the minimal age is 40
years to enter the screening study, the incidence of cancer
will be much lower than in our studies. Our own age limit is
60 years, because we try to focus on the relatively high-risk
population. 
The cost issues are obviously very important. The low-dose
fast CT screen can be done at our institution for close to
$200. I think that as the technology improves, the cost will
decrease further. 
The issue about whether or not screening will improve sur-
vival is both a medical and a political issue. I will not discuss
the political issues. However, the main argument presented by
the epidemiologists and statisticians is that lung cancer detect-
ed at an early stage may be cancer that might not otherwise be
a clinical menace. I think few physicians in this room believe
that statement to be true. It is important that we address the
argument from the standpoint of advanced disease, because
advanced disease is not going to be subject to a lead-time bias
or an over-diagnosis bias. If the disease detected by CT is less
advanced, then fewer patients will die. I think CT scanning will
prove to be an effective screening modality.
Dr Hani Shennib (Montreal, Quebec, Canada). Did you
evaluate the pathologic staging of your cancers? Have you
seen an upstaging or downstaging in comparison with what
you have noted on a chest radiograph and a CT scan? Is there
a difference in the upstaging between a CT scan and a chest
x-ray film? 
Dr Altorki. I have not looked at that, because we used the
pathology report to measure the tumor size. The data are
obviously available, but I cannot comment on them. 
Dr E. Carmack Holmes (Los Angeles, Calif). I just want
to remind you of some data from the Lung Cancer Study
Group, 821 study, in which about 800 patients with T1 N0
lesions detected by chest x-ray films were randomized to
receive lobectomy or less than lobectomy. In this population
with lesions measuring 1 cm or larger, detected on chest x-ray
films, more than 50% had benign lesions at the time of tho-
racotomy. That speaks to the issue here. I think lesions that
are detected by spiral CT and are less than 4 or 5 mm in diam-
eter are probably going to have a much higher incidence of
benignity than the experience in the Lung Cancer Study
Group. 
Dr Altorki. That is an important point. As we explore this
modality further, as I believe we should, we need to establish
the criteria for operating. Obviously if every nodule seen
results in an operation, then the cost and disadvantage to the
patient will be tremendous. 
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